NEW YORK, Aug. 6 – Venture capital firm Morgenthaler has closed $850 million in a new fund that it will use to double its early-stage investments in the health-care sector, the company said on Monday.

Morgenthaler, with offices in Cleveland and Menlo Park, Calif., has in the past invested in genomics companies including Protogene, which develops DNA microarrays, and Sequana Therapeutics, now a subsidiary of Celera Genomics as a part of Axys Pharmaceuticals.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.